Key facts
- This page summarizes David P. Perry's Form 4 filing for Evelo Biosciences, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Jun 2021, 16:06.
David P. Perry - 08 Jun 2021 Form 4 Insider Report for Evelo Biosciences, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 08 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2021, 16:06:08 UTC
- Prior SEC filing
- 01 Nov 2021
- Next SEC filing
- 01 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel S. Char, Attorney-in-Fact for David P. Perry
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David P. Perry filed Form 4 for Evelo Biosciences, Inc. on 11 Jun 2021.
Change
- Previous filing in this sequence was filed on 01 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVLO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,690
- Change %
- Price
- $0.000000
- Shares after
- 15,690
- Date
- 08 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,690
- Exercise price
- $14.60
- Footnotes
- F1
EVLO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,810
- Change %
- Price
- $0.000000
- Shares after
- 1,810
- Date
- 09 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,810
- Exercise price
- $14.19
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests on the earlier of June 8, 2022 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.